Guolian Securities released a research report on April 9 stating that Meihua Biotech (600873.SH) was given a purchase rating. The main reasons for the rating include: 1) the quantity and price of feed amino acids have risen sharply, and the performance is in line with market expectations; 2) actively laying out synthetic biology to open up room for growth; 3) maintaining high dividends and high repurchase policies over a long period of time. (Mainichi Keizai Shimbun)
国联证券4月9日发布研报称，给予梅花生物（600873.SH）买入评级。评级理由主要包括：1）饲料氨基酸量价齐升，业绩符合市场预期；2）积极布局合成生物学打开成长空间；3）长期保持高分红、高回购政策。（每日经济新闻）
Guolian Securities released a research report on April 9 stating that Meihua Biotech (600873.SH) was given a purchase rating. The main reasons for the rating include: 1) the quantity and price of feed amino acids have risen sharply, and the performance is
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.